[go: up one dir, main page]

WO1992002234A3 - Reduction ou prevention du phenomene de sensibilisation aux medicaments - Google Patents

Reduction ou prevention du phenomene de sensibilisation aux medicaments Download PDF

Info

Publication number
WO1992002234A3
WO1992002234A3 PCT/US1991/005446 US9105446W WO9202234A3 WO 1992002234 A3 WO1992002234 A3 WO 1992002234A3 US 9105446 W US9105446 W US 9105446W WO 9202234 A3 WO9202234 A3 WO 9202234A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
skin
antigen
processing
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/005446
Other languages
English (en)
Other versions
WO1992002234A2 (fr
Inventor
Philip W Ledger
Michel J-N Cormier
Alfred Amkraut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of WO1992002234A2 publication Critical patent/WO1992002234A2/fr
Publication of WO1992002234A3 publication Critical patent/WO1992002234A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention s'adresse à un procédé permettant de réduire ou de prévenir la sensibilisation de la peau par inhibition du traitement immunologique d'un médicament sensibilisant sous forme d'antigène. Le médicament est sensibilisant chez les humains c'est-à-dire, il est susceptible d'induire une sensibilisation de la peau ou des muqueuses chez une personne lorsqu'on administre transdermiquement le médicament à la personne à un rythme thérapeutiquement efficace. On induit la réduction ou la prévention de la sensibilisation de la peau par coadministration à la peau ou aux muqueuses de la personne: a) d'une quantité thérapeutiquement efficace d'un médicament sensibilisant à un rythme thérapeutiquement efficace sur une période de temps prédéterminée; et b) d'un agent inhibiteur du traitement antigénique en une quantité efficace pour inhiber le traitement antigénique du médicament. Le système de l'invention comprend une substance fondamentale adaptée pour être placée dans une relation de transmission de médicament sensibilisant et d'agent inhibiteur du traitement antigénique par rapport à l'emplacement séléctionné de la peau ou des muqueuses. La substance fondamentale renferme des quantités suffisantes du médicament et de l'agent pour permettre la coadministration en continue dudit médicament à l'emplacement de la peau ou des muqueuses, à un rythme thérapeutiquement efficace et sur une période de libération prédétérminée, et de l'agent inhibiteur du traitement antigénique, à un rythme et sur une période de temps suffisant pour inhiber le traitement du médicament sous forme d'antigène.
PCT/US1991/005446 1990-08-03 1991-08-01 Reduction ou prevention du phenomene de sensibilisation aux medicaments Ceased WO1992002234A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US562,788 1990-08-03
US07/562,788 US5120545A (en) 1990-08-03 1990-08-03 Reduction or prevention of sensitization to drugs

Publications (2)

Publication Number Publication Date
WO1992002234A2 WO1992002234A2 (fr) 1992-02-20
WO1992002234A3 true WO1992002234A3 (fr) 1992-06-11

Family

ID=24247786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/005446 Ceased WO1992002234A2 (fr) 1990-08-03 1991-08-01 Reduction ou prevention du phenomene de sensibilisation aux medicaments

Country Status (7)

Country Link
US (1) US5120545A (fr)
AU (1) AU8726991A (fr)
IE (1) IE912724A1 (fr)
MX (1) MX9100447A (fr)
PT (1) PT98550A (fr)
WO (1) WO1992002234A2 (fr)
ZA (1) ZA916065B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9101986D0 (en) * 1991-01-30 1991-03-13 Smith & Nephew Pharmaceutical compositions
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
US5843979A (en) * 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US6190894B1 (en) 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
EP0764017A4 (fr) * 1993-03-19 1997-08-06 Cellegy Pharma Inc Procedes et compositions permettant d'induire une separation de phase dans des doubles couches lipidiques epitheliales
US5451407A (en) * 1993-06-21 1995-09-19 Alza Corporation Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug
US5533971A (en) * 1993-09-03 1996-07-09 Alza Corporation Reduction of skin irritation during electrotransport
ATE165521T1 (de) * 1994-03-30 1998-05-15 Alza Corp Verminderung der hautreizung während einer iontophoretischen abgabe von medikamenten
US5498417A (en) * 1994-05-12 1996-03-12 Coating Sciences, Inc. Transdermal delivery of appetite suppressant drug
US5686100A (en) * 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5618557A (en) * 1994-11-22 1997-04-08 E.R. Squibb & Sons, Inc. Prophylactic treatment of allergic contact dermatitis
AU3309097A (en) * 1996-06-12 1998-01-07 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
US5716987A (en) 1996-06-21 1998-02-10 Bristol-Myers Squibb Company Prophylactic and therapeutic treatment of skin sensitization and irritation
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
DE19918105C1 (de) 1999-04-22 2000-09-21 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einem stark wirksamen Neuroleptikum
WO2001005381A1 (fr) * 1999-07-15 2001-01-25 Hisamitsu Pharmaceutical Co., Inc. Preparations a absorption percutanee
CN1253149C (zh) * 2001-05-31 2006-04-26 久光制药株式会社 经皮肤吸收型贴剂
US8034374B2 (en) * 2003-03-18 2011-10-11 Hisamitsu Pharmaceutical Co., Inc. Patch containing nonsteroidal anti-inflammatory and analgesic agent
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20070042026A1 (en) * 2005-03-17 2007-02-22 Wille John J Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions
WO2006127905A2 (fr) 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Dispositif d'apport de medicament portatif comprenant un element de dosage et d'administration detachable et remplaçable
EP2729148A4 (fr) 2011-07-06 2015-04-22 Parkinson S Inst Compositions et méthodes de traitement de symptômes chez des patients atteints de la maladie de parkinson
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
CA2974324A1 (fr) 2015-01-28 2016-08-04 Zita S. Netzel Procedes et systemes d'administration de medicament
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
JP7069042B2 (ja) 2016-12-28 2022-05-17 久光製薬株式会社 貼付剤
CA3049529A1 (fr) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Dispositifs et methodes d'administration transdermique de medicament
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
EP3880175A4 (fr) 2018-11-16 2022-08-17 Morningside Venture Investments Limited Système d'administration transdermique de médicaments à régulation thermique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282156A2 (fr) * 1987-03-09 1988-09-14 Alza Corporation Composition pour la prévention d'une allergie de contact par co-administration d'un corticostéroide avec un médicament sensibilisant
EP0331391A1 (fr) * 1988-03-01 1989-09-06 Alza Corporation Méthode pour réduire la sensibilité ou irritation dans la délivrance transdermique de médicaments et moyens d'application
EP0331392A2 (fr) * 1988-03-01 1989-09-06 Alza Corporation Anésthésie et antisepsie de la peau

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3991755A (en) * 1973-07-27 1976-11-16 Medicon, Inc. Iontophoresis apparatus for applying local anesthetics
US4274420A (en) * 1975-11-25 1981-06-23 Lectec Corporation Monitoring and stimulation electrode
US4141359A (en) * 1976-08-16 1979-02-27 University Of Utah Epidermal iontophoresis device
US4325367A (en) * 1977-06-13 1982-04-20 Robert Tapper Iontophoretic treatment apparatus
US4250878A (en) * 1978-11-22 1981-02-17 Motion Control, Inc. Non-invasive chemical species delivery apparatus and method
CA1153427A (fr) * 1978-12-11 1983-09-06 Patrick T. Cahalan Electrode auto-collable
WO1981000964A1 (fr) * 1979-10-10 1981-04-16 Cyclotech Med Ind Bandage inhibant la douleur
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
JPS5810066A (ja) * 1981-07-10 1983-01-20 株式会社アドバンス イオントフオレ−ゼ用プラスタ−構造体
US4419092A (en) * 1981-11-06 1983-12-06 Motion Control, Inc. Iontophoretic electrode structure
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4557723A (en) * 1983-08-18 1985-12-10 Drug Delivery Systems Inc. Applicator for the non-invasive transcutaneous delivery of medicament
US4640689A (en) * 1983-08-18 1987-02-03 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
US4708716A (en) * 1983-08-18 1987-11-24 Drug Delivery Systems Inc. Transdermal drug applicator
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4702732A (en) * 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
US4988705A (en) * 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282156A2 (fr) * 1987-03-09 1988-09-14 Alza Corporation Composition pour la prévention d'une allergie de contact par co-administration d'un corticostéroide avec un médicament sensibilisant
EP0331391A1 (fr) * 1988-03-01 1989-09-06 Alza Corporation Méthode pour réduire la sensibilité ou irritation dans la délivrance transdermique de médicaments et moyens d'application
EP0331392A2 (fr) * 1988-03-01 1989-09-06 Alza Corporation Anésthésie et antisepsie de la peau

Also Published As

Publication number Publication date
WO1992002234A2 (fr) 1992-02-20
US5120545A (en) 1992-06-09
AU8726991A (en) 1992-03-02
ZA916065B (en) 1992-04-29
IE912724A1 (en) 1992-02-12
PT98550A (pt) 1992-07-31
MX9100447A (es) 1992-04-01

Similar Documents

Publication Publication Date Title
WO1992002234A3 (fr) Reduction ou prevention du phenomene de sensibilisation aux medicaments
CA2046014A1 (fr) Reduction ou prevention des irritations cutanees causees par des medicaments
NZ508526A (en) Opioid formulations for treating pain
NO944249L (no) Transdermal administrering av oksybutynin
ATE292982T1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu- opioidanagonisten und eines kappa - 2- opioidanagonisten
BR0115392A (pt) Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
BR9507858A (pt) Aplicação de um composto inibidor de prolactina para preparar um medicamento para o tratamento de uma disfunção do sistema imunitário aplicação de um composto estimulador de prolactina para preparar um medicamento para o tratamento de uma disfunção do sistema imunitário aplicação de um composto estimulador de prolactina para preparar um medicamento para o tratamento de uma doença autoimunitária e pacote terapêutico
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
RU95105973A (ru) Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмоза
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
WO2003063573A3 (fr) Methode de traitement de maladies faisant appel a l'interferon omega
EP0754457A4 (fr) Agent anti-obesite
US4369190A (en) Analgesic composition and use thereof to ameliorate intractable pain
CA2038597A1 (fr) Methode et preparation pharmaceutique pour le soulagement de la douleur
CA2156481A1 (fr) Compositions antagonistes du recepteur 5-ht2, utiles pour le traitement des troubles veineux
MY124465A (en) Reduction of infarct volume using citicoline
CA2131991C (fr) Traitement de la migraine
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
EP0175440A3 (fr) Procédé de traitement de maux de tête dus à la migraine
BR9611671A (pt) Método de alvejamento de dosagens de medicamentos e de agentes terapêuticos e de outros glicosaminoglicanos (gags) para tratar de uma doença ou condição em um ser humano.
WO2001041771A3 (fr) Systeme transdermique contenant de l'acide acetylsalicylique pour le traitement de la migraine
WO1997026880A3 (fr) Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1
RU94016196A (ru) Способ лечения больных брюшным тифом

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA